Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Vivos Therapeutics CEO Kirk Huntsman Discusses FDA Approval and Market Disruptions

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to highlight certain significant favorable market developments creating new opportunities to widen its funnel of potential users of Vivos’ oral appliance therapies. This comes after the U.S. FDA granted, for the first time ever, a clearance to the Vivos CARE appliances to treat moderate and severe OSA in adults, (18 years of age and older) with positive airway pressure and/or myofunctional therapy, as needed. Huntsman highlighted several other factors contributing to the positive market conditions for Vivos. The recent discontinuation of many devices by Philips Respironics is expected to disrupt the supply chain, potentially affecting patient care. Additionally, the recalls of continuous positive airway pressure (CPAP) devices have left millions of OSA sufferers searching for alternative treatments. United Healthcare's recognition of oral appliance therapy as a prerequisite for surgical treatment in adult patients with moderate to severe OSA is another important development. These factors are collectively creating a significant opportunity for Vivos to expand its user base and offer effective treatment options to those in need. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

February 12, 2024 09:24 AM Eastern Standard Time

Video

Roberts & Ryan Inc., America's first Service-Disabled Veteran-Owned (SDVO) broker-dealer, is pleased to welcome Andrew Reynolds as its newest Managing Director.

Roberts & Ryan, Inc.

Andrew Reynolds joins Roberts & Ryan as Managing Director and has more than 30 years of experience in equity trading, capital markets, portfolio management, options & derivatives, sales & business development, investor relations, and corporate compliance. Prior to joining Roberts & Ryan, Mr. Reynolds was Head of Equity Trading and a Registered Principal at Tullett Prebon and KCCI Ltd. Before that, he was Head Trader and Floor Broker at Tradition North America and R.J. Murphy & Associates. Prior to that, he was Head Trader at Preferred Technology. Mr. Reynolds began his career as an Options Clerk at Pershing, LLC. “Andrew brings extensive experience in equity trading and represents Roberts & Ryan’s commitment to providing best in class service and execution,” said James McDevitt, Roberts & Ryan’s Senior Director of Equity Sales and Trading, Capital Markets. “He will be a tremendous advocate for our social mission of supporting veterans and their families. I’m very excited to have him join our team.” Mr. Reynolds is a member of the Securities Traders Association (STA), the Securities Traders Association of New York (STANY), Philadelphia Traders (ITAP), and the National Investor Relations Institute (NIRI). He holds SIE and FINRA Series 7, 24, 25, 55, 57 & 63 licenses. Mr. Reynolds served as a Technical Warfare Specialist, Team Leader, and Group Leader in the 25 th Infantry Division of the United States Army and is a graduate of Archbishop Ryan in Philadelphia. About Roberts and Ryan, Inc. Roberts & Ryan, Inc. is a Service-Disabled Veteran Owned (SDVO) broker-dealer with execution capabilities in the capital markets, equities, and fixed-income trading. The firm was founded in 1987 by a United States Marine Corps Vietnam combat veteran and Purple Heart recipient. With over $1.8 million in committed donations, Roberts & Ryan is active in donating to charitable foundations that make significant positive impacts in the lives of Veterans and their families, focusing primarily on general wellness, mental health, and career transition. To learn more about Roberts & Ryan, please visit www.roberts-ryan.com. Contact Details Michael C. Del Priore +1 646-859-4061 mdelpriore@roberts-ryan.com Company Website https://www.roberts-ryan.com

February 12, 2024 09:00 AM Eastern Standard Time

Image

Building on success of first marketing campaign, 1606 Corp launches second one with Cannasite

1606 Corp.

1606 Corp CEO Greg Lambrect discussed the company's innovative marketing campaign in collaboration with its ISO partner, Cannasite, in an interview with Steve Darling from Proactive. The campaign is designed to engage Cannasite's extensive network of over 300 clients through targeted outreach, including email and calls. Following the success of their December marketing initiative for ChatCBDW with Cool Blue Distribution, Lambrect emphasized that the new campaign with Cannasite comes with higher expectations. The primary goal of the campaign is to expand the reach within the online brand community and solidify ChatCBDW's position as a pivotal tool in revolutionizing customer service and sales processes. Cannasite, a leading provider of web design and digital marketing services in the cannabis industry, has a strong client base and significant industry connections. Their partnership with 1606 Corp aims to revolutionize the AI merchandising landscape in the cannabis sector. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 12, 2024 08:22 AM Eastern Standard Time

Video

Poolbeg Pharma says research confirms $10B plus opportunity for POLB 001 in cancer immunotherapies

Poolbeg Pharma PLC

Poolbeg Pharma Plc chief business officer David Allmond joined Proactive's Stephen Gunnion with details of independent research that confirms the massive market potential for Poolbeg's POLP 001 in cancer immunotherapies. This asset is being explored for its ability to potentially prevent or treat cytokine release syndrome (CRS), a significant side effect of cancer immunotherapies. With the cancer immunotherapy market expected to reach $140 billion by 2030, POLB 001 presents an over $10 billion opportunity if successful. Additionally, Allmond elaborated on Poolbeg's increasing emphasis on rare and orphan diseases, leveraging its ongoing programs in influenza with POLB 001, obesity, metabolic conditions, and AI-driven discovery for novel targets. The company is actively considering strategies to acquire near-stage commercial or in-market products in this high unmet need, limited competition sector. This approach aligns with Poolbeg's evolution towards a commercial-stage organization, aiming to generate revenue and continue its growth trajectory. Furthermore, Allmond explained how POLB 001 fits into the rare orphan disease space, given its potential applications in orphan cancers where immunotherapies have shown success. Poolbeg's strategic pivot towards rare and orphan diseases complements its existing portfolio, aiming for a dual-track growth strategy focusing on both its current programs and commercial opportunities in the rare and orphan disease market. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 08:03 AM Eastern Standard Time

Video

Creo Medical ends "pivotal" 2023 year with clear path to cashflow breakeven

Creo Medical Group PLC

Creo Medical Group CEO Craig Gulliford tells Proactive's Stephen Gunnion that 2023 was a pivotal year for the company. Amid challenging market conditions, Creo successfully secured crucial funding, setting a foundation for enhanced operational focus rather than fundraising efforts. Key milestones included the launch of the Speedboat UltraSlim, a significant advancement in minimising medical device size, which led to the company's largest quarter in orders and technology uptake. This innovation, alongside the early market release of selected products, received positive feedback and significant regulatory clearances in the US and Europe, propelling Creo towards a robust setup for 2024. Furthermore, Creo announced progress with its SpydrBlade and MicroBlate programs, showcasing advancements in surgical technology and partnerships with leading robotic surgery firms. Financially, Creo reported a 13% revenue increase to £30.8 million and a 10% reduction in operating costs, reflecting strategic shifts towards more cost-effective and revenue-generating operations. These developments signal Creo's transition into a fully commercial business, with a clear path to cash flow breakeven by 2025. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 12, 2024 07:43 AM Eastern Standard Time

Video

BlackRock Acquires Stake In Cardio Diagnostics

Cardio Diagnostics Holdings, Inc

By Jeremy Golden, Benzinga BlackRock (NYSE: BLK) has acquired a minor stake in Cardio Diagnostics (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company. In BlackRock’s 13G filing on Feb. 2, they disclosed ownership representing 5.2% of Cardio Diagnostics. Fintel reports that the average one-year price target for Cardio Diagnostics is $6.12, and forecasts range from a low of $4.04 to a high of $8.40. Cardio Diagnostics had Weighted-Average Shares Outstanding (Diluted) of 11.90 million for the most recently reported fiscal quarter, ending Sept. 30, 2023. Cardio Diagnostics’ stock has an ownership structure of institutional, retail and individual investors. About 1.84% of the company’s stock is owned by institutional investors, while 18.58% is owned by insiders. About 79.58% is owned by public companies and individual investors. Prelude Capital Management, Geode Capital Management and Vanguard Group are the biggest institutional shareholders, with 121,000, 75,483 and 64,022 shares, respectively. About Cardio Diagnostics Cardio Diagnostics was formed to develop and commercialize clinical tests that leverage artificial intelligence-driven technology to combat cardiovascular disease. The company is behind PrecisionCHD, the first integrated genetic-epigenetic test for the detection of coronary heart disease (CHD), the most common type of heart disease and the cause of most heart attacks. With the introduction of PrecisionCHD, clinicians are armed with a powerful, scalable and non-invasive alternative that comes in the form of a blood-based test that uses artificial intelligence (AI), along with personalized genetic and epigenetic information, to sensitively detect the presence of CHD. Cardio Diagnostics has also developed Epi+Gen CHD, a powerful test that predicts the three-year risk for a CHD event, mainly a heart attack. Powered by AI-driven integrated genetics and epigenetics, the tool enables more effective decision-making and earlier interventions. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

February 09, 2024 08:30 AM Eastern Standard Time

Cannara Biotech CFO Nicholas Sosiak: Unveiling Success Strategies and Future Plans

Cannara Biotech Inc

Cannara Biotech Inc CFO Nicholas Sosiak joined Steve Darling from Proactive to provided valuable insights into the company's success in the cannabis industry. Cannara, based in Montreal, Canada, is a licensed producer with two facilities totaling 1.6 million square feet, with a strong focus on quality and cost-efficiency, thanks in part to Quebec's low electricity costs. Sosiak discussed the company's strategic acquisitions, including the purchase of a 1 million square foot cannabis facility for $27 million, significantly below its initial cost. Cannara Biotech Inc. has also developed three in-house brands: Tribal, Nugs, and Orchid CBD, each catering to specific market niches. The company places a strong emphasis on consistency and quality to drive brand loyalty among consumers. As CFO, Sosiak combines his financial expertise with a passion for the cannabis industry. His leadership has contributed to the company's impressive 60% increase in net revenue. Looking ahead to 2024, Cannara Biotech plans to capitalize on its existing markets, introduce new products, and expand into untapped regions. Sosiak expressed optimism about the potential for international growth, particularly in the US market, once regulatory barriers are addressed. Cannara Biotech Inc. is currently traded on the TSXV (LOVE) and OTCQB (LOVFF), with plans to enhance visibility among US investors in the future. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 08, 2024 09:37 AM Eastern Standard Time

Video

Theralase Technologies shares update on Phase II Bladder Cancer study

Theralase Technologies Inc

Theralase Technologies CEO Roger DuMoulin-White joined Steve Darling from Proactive to share details of an update on the company's Phase II Non-Muscle Invasive Bladder Cancer clinical study. DuMoulin-White shared the significant findings from the study, revealing that it has provided the primary study treatment to 63 patients. The interim clinical data from Study II shows promising results, with a Complete Response (CR) rate of 54% at 6 months, 38% at 12 months, and 37% at 15 months. These CR rates surpass the guidelines set by the International Bladder Cancer Group (IBCG). Additionally, at the 90 Day Assessment Visit, 56% of Evaluable Patients achieved a CR, and 63% achieved a Total Response (CR + IR). At 450 days, 37% achieved a CR, and 41% achieved a TR. The interim clinical data for patients who received the optimized Study II Treatment is even more encouraging. At the 90 Day Assessment Visit, 62% of Evaluable Patients achieved a CR, and 68% achieved a Total Response (CR + IR). At 450 days, 39% achieved a CR, and 44% achieved a TR. These positive results demonstrate the potential of Theralase Technologies' treatment approach in addressing Non-Muscle Invasive Bladder Cancer. The company continues to advance its research and clinical studies, bringing hope to patients and the medical community alike. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 08, 2024 09:34 AM Eastern Standard Time

Video

First-Ever Risk Retention Group for the Cannabis Industry Launches with CLIC RRG

IMA Financial

Cornerstone Risk Solutions, a subsidiary of IMA Financial Group, today announced the launch of CLIC Risk Retention Group Inc. (CLIC RRG), the first and only risk retention group designed specifically for the unique needs of the burgeoning cannabis industry. The member-owned insurance solution is now available to cannabis-related businesses (CRBs) nationwide. “We are very proud to announce the launch of CLIC Risk Retention Group. We are the first and only insurer in the cannabis space that is owned exclusively by its policyholders,” said Chris Payne, founder of CLIC RRG. “This allows us to offer risk management and profit-sharing opportunities that are unavailable anywhere else in the industry.” The product represents a significant step toward comprehensive insurance solutions tailored to the needs of CRBs across the United States. CLIC members gain access to general liability and product liability coverage from anywhere in the nation, which until now has been out of reach in this high-risk, heavily legislated sector. Tris Felix, Managing Director of Cornerstone Risk Solutions, highlighted the product’s significance: “A member-owned insurance solution is a game-changer for CRB owners whose growth has been historically limited by lack of liability coverage. CLIC RRG owners can build — and benefit from — products that meet the industry’s unique needs, leveling the playing field in a competitive and evolving industry.” As the cannabis industry continues to grow, Cornerstone and CLIC RRG are committed to assessing market responses and potentially introducing additional cannabis industry-specific insurance solutions. “Historically, CLIC RRG coverage lines have been profitable for carriers, yet restricted the policyholders,” said IMA Vice President and Cannabis National Practice Leader Michael Hennessey. “By coming together in a risk retention group, cannabis businesses set their own direction and claim their due benefit.” About Cornerstone Risk Solutions and IMA Financial Group Cornerstone Risk Solutions, a subsidiary of IMA Financial Group, specializes in providing innovative insurance and risk management solutions. IMA Financial Group, a North American insurance brokerage firm, is renowned for its commitment to protecting assets and making a difference in the lives of its clients, associates and communities. About CLIC Risk Retention Group Inc. (CLIC RRG) CLIC Risk Retention Group Inc. (CLIC RRG) is a private insurance company owned by and operated solely for the benefit of participants in the legalized cannabis industry. The company serves businesses and individuals involved in the sale, manufacture, cultivation, transportation and testing of legalized cannabis-based products. The company’s operations are controlled by policyholders who are licensees in the cannabis industry. Contact Details CLIC Risk Retention Group Inc. Chris Payne +1 858-260-9000 chris@clicrrg.com IMA Financial Group Sean Hanft +1 203-313-3205 Sean.hanft@imacorp.com Center Reach Communications Alexandra Campbell alexandra@centerreachcommunication.com Company Website https://cornerstonerisksolutions.com/

February 08, 2024 09:00 AM Eastern Standard Time

Image

1 ... 46 47 48 49 50 ... 251